ArticleMethods in molecular biology (Clifton, N.J.)2008
Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen.
Article in Methods in molecular biology (Clifton, N.J.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Ultraviolet C inactivation of Coxiella burnetii for production of a structurally preserved whole cell vaccine antigen.BMC microbiology · 2024Article
- Article
- Inactivation of aerosolized SARS-CoV-2 by 254 nm UV-C irradiation.Indoor air · 2022Article
- Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges.Biomedicines · 2021Review
- Coronavirus seasonality, respiratory infections and weather.BMC infectious diseases · 2021Article
- Rapid, dose-dependent and efficient inactivation of surface dried SARS-CoV-2 by 254 nm UV-C irradiation.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Article
- Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.Advanced nanobiomed research · 2021Article
- UV, ozone, and COVID-19 transmission in Ontario, Canada using generalised linear models.Environmental research · 2021Article
- SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies.Asian journal of pharmaceutical sciences · 2021Review
- Portable Ultraviolet-C Chambers for Inactivation of SARS-CoV-2.Journal of research of the National Institute of Standards and Technology · 2021Article
- Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development.Pathogens (Basel, Switzerland) · 2020Review
- Vaccination strategies to combat novel corona virus SARS-CoV-2.Life sciences · 2020Review
- The Current Status of COVID-19 Vaccines.Frontiers in genome editing · 2020Review
- Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.Journal of virology · 2014Article
- SARS vaccines: where are we?Expert review of vaccines · 2009Review
- Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2.Avicenna journal of medical biotechnologyArticle
- Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges.Diabetes & metabolic syndromeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In general, a whole virion serves as a simple vaccine antigen and often essential material for the analysis of immune responses against virus infection. However, to work with highly contagious pathogens, it is necessary to take precautions against laboratory-acquired infection. We have learned many lessons from the recent outbreak of severe acute respiratory syndrome (SARS). In order to develop an effective vaccine and diagnostic tools, we prepared UV-inactivated SARS coronavirus on a large scale under the strict Biosafety Level 3 (BSL3) regulation. Our protocol for large-scale preparation of UV-inactivated SARS-CoV including virus expansion, titration, inactivation, and ultracentrifugation is applicable to any newly emerging virus we might encounter in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.